Raptor Pharmaceuticals Provides Update of Product Programs



    
    Poster at Upcoming International Liver Cancer Conference

    Status of Ongoing Programs

    Regulatory Consulting Firm Retained
    

    NOVATO, Calif., Sept. 13 /CNW/ -- Raptor Pharmaceuticals Corp. ("Raptor"
or the "Company") (OTC Bulletin Board:   RPTP.OB) announced today that Dr. Todd
Zankel, the Company's Chief Scientific Officer, will present a poster
detailing promising preclinical results from two preclinical studies of its
HepTide(TM) liver targeting program at the International Liver Cancer ("ILCA")
Conference, to be held October 5-7, 2007 in Barcelona, Spain.
    Dr. Zankel's presentation will include an update on Raptor's liver
targeting platform based on human receptor-associated protein ("RAP").  For
more information on ILCA and the 2007 ILCA Conference, please visit www.ilca-
online.org. A synopsis of the poster will be available in the investor
relations section of Raptor's website at www.raptorpharma.com shortly after
Dr. Zankel presents at the conference.
    
    Current Program Updates:
    
    Investigational New Drug Application ("IND")-Enabling Studies Initiated
for HepTide(TM)
    Based on promising results from ongoing preclinical studies of its RAP
liver targeting program, Raptor has initiated a pre-IND program for
HepTide(TM) (its liver targeting therapeutic conjugate using the RAP targeting
platform).  The Company's goal is to file an IND for this therapeutic
conjugate with the Food and Drug Administration (the "FDA") by the end of the
second calendar quarter of 2008.  To help execute this plan the Company has
retained Regulatory Professionals, Inc., a regulatory consulting firm
experienced in working with the FDA in all aspects of regulatory affairs
including preclinical and clinical support for pre- and post-approval
products, and preparation and submission of regulatory filings for marketing
approval.
    Donna Kato, the CEO of Regulatory Professionals, Inc. stated, "We are
very excited to be working with Raptor as it advances toward clinical trials."
    Dr. Christopher Starr, Raptor's CEO stated, "Building an internal team of
high-quality individuals would take a great deal of time and money, while
Donna and her team provide us access to the best talent under a tight
development timeline and operational flexibility essential to an emerging
company." More information on Regulatory Professionals, Inc. can be found on
their website www.regprofessional.com.
    In addition, Raptor has initiated proof-of-principle preclinical studies
targeting a new therapeutic area:  the use of the HepTide delivery molecule to
enhance the distribution of antiviral drugs to the liver for the treatment of
viral hepatitis.  HepTide has shown strong hepatotrophic activity by binding
selectively to liver cells or to infected liver cells in preclinical studies.
Conjugates of HepTide and antiviral agents could significantly improve
accumulation of these agents in the liver and reduce the amount of powerful
antiviral agents elsewhere in the body.
    Stanford University Grant Renewed for NeuroTrans(TM) in Neurodegenerative
Diseases
    Based on promising early results in blood-brain barrier ("BBB") transport
models from its collaboration initiated in August 2006, Raptor has renewed its
grant with Dr. William Mobley's neuroscience laboratory at Stanford
University.  In the first year of the collaboration, a number of RAP peptides
were tested for their ability to cross the BBB.  From these experiments, the
team selected a lead candidate transport peptide called RAP-2s.  In this
second year, the team will continue to assess the bio-distribution of RAP-2s
within various brain compartments, commence testing of RAP-2s' ability to
deliver Nerve Growth Factor ("NGF") across the BBB, and to investigate the
potential for RAP-NGF conjugates to prevent or reverse neuronal injury in
preclinical models.
    
    Preclinical Testing Completed for WntTide(TM) in Osteoporosis
    
    Raptor has completed preclinical testing of WntTide, for its osteoporosis
program, utilizing Mesd and engineered Mesd-based peptides, and is awaiting
the final report of WntTide in a well-accepted preclinical model widely used
to test reduction in bone loss. WntTide may aid in increasing bone density in
the treatment of osteoporosis and rheumatoid arthritis.  The Company has run
selected preclinical studies to move this program to a point where its utility
can be realistically assessed for further investment.  If results are
positive, the Company plans to seek a collaborative arrangement with a partner
for further development of the peptide in this very widespread and expensive
disease. The Company licensed Mesd from Washington University, St. Louis, for
the treatment of osteoporosis and cancer in November 2006.
    
    Scientific Publication Update
    
    Raptor researchers published a paper entitled "Minimization of the third
domain of the LDL receptor-associated protein (RAP)," which describes their
efforts to develop a readily-manufactured RAP-based peptide to act as a
delivery vehicle to the liver.  Raptor authors include Sara Isbell, Simone
Haslam and Dr. Todd Zankel. The Internet link to the paper, published by
Biochemical and Biophysical Research Communications dated September 28, 2007
in volume 361, issue 3, pages 758 to 762, will be posted in the Product
Programs, RAP section of our website www.raptorpharma.com.
    
    About Raptor
    
    Raptor Pharmaceuticals Corp.'s sole business is its 100% ownership of
Raptor Pharmaceutical Inc., a development stage biotechnology company which
bioengineers novel drugs and drug-targeting platforms derived from the human
receptor-associated protein ("RAP") and related proteins. The Company's
preclinical programs target cancer, neurodegenerative disorders, infectious
diseases and osteoporosis. HepTide(TM) utilizes engineered RAP-based peptides
conjugated to drugs to target their delivery to the liver. In
neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are
currently undergoing evaluation at Stanford University in cell culture and
preclinical models for their ability to enhance the transport of molecules
from blood to brain.  In osteoporosis, Raptor is testing the ability of
WntTide, which are Mesd and engineered Mesd-based peptides and act through
LRP5, a known determinant of bone density, to combat osteoporosis and increase
bone density. In an effort to protect its novel approach, Raptor currently has
five patent applications in review in the U.S., and countries in Europe and
Asia, as well as two provisional patent applications licensed from Washington
University.  In addition, the Company has recently submitted two new
provisional patent applications in the U.S., the first of which covers a new
family of RAP peptides, with the second application to further support and
expand the Company's coverage in specific disease indications. For additional
information, please visit www.raptorpharma.com.
    
    FORWARD LOOKING STATEMENTS
    
    This document contains forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. These statements
relate to future events, but are not limited to the ability of RAP to
conjugate to drugs or to target the liver, the ability of RAP peptides to
enhance the transport of molecules from blood to the brain, the ability of
Mesd or Mesd-based peptides to combat osteoporosis and increase bone density.
These statements are only predictions and involve known and unknown risks,
uncertainties and other factors, which may cause the Company's actual results
to be materially different from these forward-looking statements. Factors
which may significantly change or prevent the Company's forward looking
statements from fruition include that the Company may be unsuccessful in
developing any products; that its technology may not be validated as the
Company progresses further and its methods may not be accepted by the
scientific community; that the Company is unable to retain or attract key
employees whose knowledge is essential to the development of its products;
that unforeseen scientific difficulties develop with the Company's process;
that the Company's patents are not sufficient to protect essential aspects of
its technology; that competitors may invent better technology; that the
Company's products may not work as well as hoped or worse, that the Company's
products may harm recipients; and that the Company may not be able to raise
sufficient funds for development or working capital when required. As well,
the Company's products may never develop into useful products and even if they
do, they may not be approved for sale to the public. The Company cautions
readers not to place undue reliance on any such forward-looking statements,
which speak only as of the date they were made. Certain of these risks,
uncertainties, and other factors are described in greater detail in the
Company's filings from time to time with the Securities and Exchange
Commission ("SEC"), which we strongly urge you to read and consider, including
the Company's Registration Statement on Form SB-2, as amended, that was
declared effective on July 10, 2006, the Company's annual report on Form 10-
KSB and Form 10-KSB/A filed with the SEC on November 22, 2006, and January 18,
2007, respectively, and the Company's quarterly report Form 10-QSB filed with
the SEC on June 29, 2007, all of which are available free of charge on the
SEC's web site at http://www.sec.gov.
    Subsequent written and oral forward-looking statements attributable to
the Company or to persons acting on behalf of the Company are expressly
qualified in their entirety by the cautionary statements set forth in its
reports filed with the SEC. The Company expressly disclaims any intent or
obligation to update any forward-looking statements.

    
    For more information, please contact:
    The Ruth Group
    Sara Ephraim (investors)
    (646) 536-7002
    sephraim@theruthgroup.com
    

    
    Janine McCargo (media)
    (646) 536-7033
    jmccargo@theruthgroup.com
    




For further information:

For further information: Investors: Sara Ephraim, +1-646-536-7002, 
sephraim@theruthgroup.com, or Media: Janine McCargo, +1-646-536-7033, 
jmccargo@theruthgroup.com, both of The Ruth Group for Raptor Pharmaceuticals 
Corp. Web Site: http://www.ilca-online.org                 
http://www.raptorpharma.com                  http://www.regprofessional.com

Organization Profile

RAPTOR PHARMACEUTICAL CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890